MY134778A - Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization - Google Patents
Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularizationInfo
- Publication number
- MY134778A MY134778A MYPI96004371A MYPI9604371A MY134778A MY 134778 A MY134778 A MY 134778A MY PI96004371 A MYPI96004371 A MY PI96004371A MY PI9604371 A MYPI9604371 A MY PI9604371A MY 134778 A MY134778 A MY 134778A
- Authority
- MY
- Malaysia
- Prior art keywords
- dna
- hyaluronic acid
- gene therapy
- treat abnormal
- retinal vascularization
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22027—Cathepsin S (3.4.22.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/23—Aspartic endopeptidases (3.4.23)
- C12Y304/23005—Cathepsin D (3.4.23.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN6161A AUPN616195A0 (en) | 1995-10-23 | 1995-10-23 | Method and composition for treatment of ocular diseases |
AUPN9047A AUPN904796A0 (en) | 1996-04-01 | 1996-04-01 | Method and composition for treatment of ocular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MY134778A true MY134778A (en) | 2007-12-31 |
Family
ID=25645043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI96004371A MY134778A (en) | 1995-10-23 | 1996-10-22 | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0859636A4 (zh) |
JP (1) | JP2000507915A (zh) |
KR (1) | KR19990066967A (zh) |
CN (1) | CN1209068A (zh) |
CA (1) | CA2235685A1 (zh) |
MY (1) | MY134778A (zh) |
NZ (1) | NZ320006A (zh) |
WO (1) | WO1997015330A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU739601B2 (en) | 1991-07-03 | 2001-10-18 | Meditech Research Limited | Use of hyaluronan in gene therapy |
US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
EP0963196B1 (en) | 1996-09-27 | 2005-01-19 | Jagotec Ag | Hyaluronic drug delivery system |
GB9723780D0 (en) * | 1997-11-12 | 1998-01-07 | Univ Manchester | Regulation of ocular angiogenesis |
SE9904121D0 (sv) | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobe biomolecular structure |
EP1242608A2 (en) * | 1999-12-28 | 2002-09-25 | Novartis AG | Method of achieving persistent transgene expression |
DE60142899D1 (de) * | 2000-06-20 | 2010-10-07 | Dainippon Sumitomo Pharma Co | Verbindungen für den transfer von oligonukleotiden |
CA2451603C (en) | 2001-06-20 | 2012-07-10 | Sumitomo Pharmaceuticals Co., Ltd. | Process for facilitating nucleic acid transfer |
WO2003070256A1 (en) * | 2002-02-15 | 2003-08-28 | Research Development Foundation | Hyaluronic acid mediated adenoviral transduction |
US7358224B2 (en) | 2003-05-29 | 2008-04-15 | The University Of Manchester | Class III SLRP agonists for the reduction of blood vessel formation |
WO2006041625A2 (en) * | 2004-10-05 | 2006-04-20 | University Of Pittsburgh - Of The Commonwealth | Method and apparatus for screening for retinopathy |
EP2447281B1 (en) | 2005-03-24 | 2015-12-16 | ThromboGenics N.V. | Novel anti-PLGF antibody |
WO2007003609A1 (en) | 2005-06-30 | 2007-01-11 | Vib Vzw | Treatment of liver cirrhosis and its complications |
CN1742623A (zh) * | 2005-07-13 | 2006-03-08 | 凌沛学 | 透明质酸磷脂复合物及其制备方法 |
ES2592902T3 (es) | 2008-10-02 | 2016-12-02 | Vib Vzw | Inhibición del PlGF para el tratamiento de la leucemia positiva para el cromosoma Filadelfia |
DK2785739T3 (en) | 2011-12-01 | 2017-07-03 | Thrombogenics Nv | IMPROVING THE RESULT OF TREASURE CULECTOMY |
KR101420751B1 (ko) * | 2011-12-12 | 2014-07-17 | 서강대학교산학협력단 | 망막 질환 치료제 후보물질의 스크리닝 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2636339B1 (fr) * | 1988-09-09 | 1992-07-17 | Auge Pier | Gel aqueux a base d'acide hyaluronique et d'acide desoxyribonucleique utilisable en cosmetique, et procede de preparation |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
WO1992013063A1 (en) * | 1991-01-18 | 1992-08-06 | Oncogene Science, Inc. | Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes |
US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
US6410322B1 (en) * | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
EP0769552A4 (en) * | 1994-06-27 | 1997-06-18 | Toagosei Co Ltd | ANTISENSE NUCLEIC ACID COMPOUND |
-
1996
- 1996-10-22 EP EP96934189A patent/EP0859636A4/en not_active Withdrawn
- 1996-10-22 CA CA002235685A patent/CA2235685A1/en not_active Abandoned
- 1996-10-22 CN CN96199290A patent/CN1209068A/zh active Pending
- 1996-10-22 MY MYPI96004371A patent/MY134778A/en unknown
- 1996-10-22 KR KR1019980702900A patent/KR19990066967A/ko not_active Application Discontinuation
- 1996-10-22 NZ NZ320006A patent/NZ320006A/en unknown
- 1996-10-22 JP JP9516137A patent/JP2000507915A/ja active Pending
- 1996-10-22 WO PCT/AU1996/000664 patent/WO1997015330A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ320006A (en) | 2001-12-21 |
CA2235685A1 (en) | 1997-05-01 |
WO1997015330A1 (en) | 1997-05-01 |
KR19990066967A (ko) | 1999-08-16 |
EP0859636A1 (en) | 1998-08-26 |
CN1209068A (zh) | 1999-02-24 |
EP0859636A4 (en) | 2002-05-02 |
JP2000507915A (ja) | 2000-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY134778A (en) | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization | |
DK0928335T3 (da) | Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider | |
DE69400208D1 (en) | Olionukleotidalkylphosphonate und -phosphonothioate | |
CA2229171A1 (en) | Method of modulating gene expression with reduced immunostimulatory response | |
WO1996023065A3 (en) | Inhibition of neovascularization using vegf-specific oligonucleotides | |
WO2001048190A3 (en) | Therapeutic uses of lna-modified oligonucleotides | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
EP0939621A4 (en) | INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODE OXYNUCLEOTIDE | |
PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
BR9608402A (pt) | Oligonucleotìdeo anti-sentido, e, processos para inibição da expressão do raf humano, da hiperproliferação de células e para tratamento da condição proliferativa anormal. | |
EP2252688A1 (en) | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof | |
DE69635349D1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
ZA981609B (en) | Method of treating a tumor | |
AU2672099A (en) | Compositions and methods for wound healing | |
NO991292L (no) | Anvendelse av benzopyranoler for Õ behandle nevrologiske forstyrrelser | |
DE69625919D1 (de) | Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation | |
ATE218372T1 (de) | Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren | |
ATE391777T1 (de) | Verwendung von prohibitin-rns in krebsbehandlung | |
AU7266496A (en) | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization | |
HK1077306A1 (en) | Ocular gene therapy | |
EP1374909A3 (en) | Evaluation of, delivery of, and use of agents to treat heart disorders | |
UA10281C2 (uk) | Спосіб отримання речовини для лікування захворювань підшлункової залози | |
MX9709866A (es) | Metodo para el tratamiento de enfermedades de pulmon utilizando oligonucleotidos antisentido. |